Based on the key indicators related to Inhibikase Therapeutics' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Inhibikase Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January. At this time, Inhibikase Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Net Invested Capital is likely to gain to about 14 M in 2024, whereas Net Receivables is likely to drop slightly above 34.1 K in 2024. Key indicators impacting Inhibikase Therapeutics' financial strength include:
The financial analysis of Inhibikase Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Inhibikase Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(18.08 Million)
Inhibikase
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Research And Ddevelopement To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Cash Flow Coverage Ratios
Price To Book Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Net Borrowings
Other Cashflows From Financing Activities
Total Cash From Operating Activities
Change To Operating Activities
Change To Netincome
Change To Liabilities
Change In Cash
Change To Account Receivables
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Inventory
Investments
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Non Cash Items
Issuance Of Capital Stock
Total Current Liabilities
Net Tangible Assets
Retained Earnings
Accounts Payable
Other Assets
Net Receivables
Total Current Assets
Common Stock
Other Current Liab
Total Assets
Short Long Term Debt Total
Total Stockholder Equity
Current Deferred Revenue
Net Debt
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Short Long Term Debt
Capital Stock
Net Working Capital
Short Term Debt
Interest Expense
Net Income Applicable To Common Shares
Ebit
Net Interest Income
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Depreciation And Amortization
Cost Of Revenue
Income Tax Expense
Probability Of Bankruptcy
Understanding current and past Inhibikase Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Inhibikase Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Inhibikase Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Inhibikase Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Inhibikase Therapeutics. Check Inhibikase Therapeutics' Beneish M Score to see the likelihood of Inhibikase Therapeutics' management manipulating its earnings.
Inhibikase Therapeutics Stock Summary
Inhibikase Therapeutics competes with DiaMedica Therapeutics, Milestone Pharmaceuticals, Seres Therapeutics, Oncolytics Biotech, and Scpharmaceuticals. Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinsons Disease and related disorders that arise inside and outside of the brain. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia. Inhibikase Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Inhibikase Therapeutics Key Income Statement Accounts
The reason investors look at the income statement is to determine what Inhibikase Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Inhibikase Therapeutics's current stock value. Our valuation model uses many indicators to compare Inhibikase Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Inhibikase Therapeutics competition to find correlations between indicators driving Inhibikase Therapeutics's intrinsic value. More Info.
Inhibikase Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Inhibikase Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Inhibikase Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Inhibikase Therapeutics Systematic Risk
Inhibikase Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Inhibikase Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Inhibikase Therapeutics correlated with the market. If Beta is less than 0 Inhibikase Therapeutics generally moves in the opposite direction as compared to the market. If Inhibikase Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Inhibikase Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Inhibikase Therapeutics is generally in the same direction as the market. If Beta > 1 Inhibikase Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Inhibikase Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Inhibikase Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Inhibikase Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.0209
At this time, Inhibikase Therapeutics' Price Earnings To Growth Ratio is comparatively stable compared to the past year.
Inhibikase Therapeutics December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Inhibikase Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Inhibikase Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Inhibikase Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Inhibikase Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Inhibikase Therapeutics's daily price indicators and compare them against related drivers.
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.